Familiar
Familiar translates proven human medicines into novel therapeutics and companion diagnostics for companion animals, addressing the gap between the rapid pace of human drug development and the limited availability of veterinary treatments. The company focuses on small molecules with validated targets and established safety data, targeting cancers, autoimmune conditions, and metabolic diseases that affect both humans and pets. Its approach also includes point-of-care diagnostics designed to identify patients most likely to benefit from treatment and monitor therapeutic response.
- Biotechnology
- Drug Discovery & Therapeutics
- Hardware
- Healthcare Technology
- Software Only
Funding
Founders
Product
Problem
Pets develop many of the same cancers, autoimmune conditions, and metabolic diseases that affect humans, driven by the same underlying biology. However, while the FDA approved 50 novel drugs for humans in 2024 alone, fewer than 5 new drugs are approved for companion animals each year, leaving veterinarians with limited treatment options despite validated human science existing for these conditions.
Solution
Familiar bridges the gap between human and veterinary medicine by taking proven human drug candidates—small molecules with validated targets and established safety data—and translating them into novel therapeutics for companion animals. The company's proprietary pipeline prioritizes indications where human science is furthest ahead and veterinary need is greatest, advancing programs only when cross-species work confirms their validity. Familiar also develops companion diagnostics designed to identify patients most likely to benefit from treatment and to monitor response, closing the loop between detection and care. By focusing on small molecules, the company ensures therapies are scalable, manufacturable, and deliverable through every veterinary clinic, not just specialty centers, maximizing access for pets everywhere.
Target Audience
Primary customers are veterinary clinics, companion animal hospitals, and veterinarians seeking modern therapeutic options and diagnostic tools for pets with cancer, autoimmune, and metabolic diseases.
Features
- Translational pipeline that repurposes human-approved small molecules with validated targets and established safety profiles for veterinary use
- Programs targeting cancers, autoimmune conditions, and metabolic diseases where human science is furthest advanced and veterinary need is highest
- Point-of-care companion diagnostics that identify patients most likely to benefit from treatment and monitor therapeutic response
- Cross-species biology approach that enables insights to flow bidirectionally between human and veterinary medicine
- Small-molecule focus ensuring scalability, manufacturability, and delivery through any veterinary clinic